TheranosticTrials.org

Clinical Trial · NCT02204462

FBnTP Imaging of Breast Cancer

Overview

Our preclinical studies suggest the capacity of the positron emission tomography imaging agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast tumors (e.g., DCIS), and differentiates benign from malignant masses with better accuracy than that obtained by existing breast imaging tools.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase

Phase 1

Contacts

Martin Pomper, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02204462

Drug / Compound

FBnTP

Isotope(s):
Target(s):
  • Mitochondria-Targeting Moieties
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Age \> 25 Ability and willingness to sign informed consent prior to any study procedure.
  • * Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer)
  • Ability to undergo up to 90 minutes of PEM imaging.
  • Positive indication of disease on mammogram or MRI scan.
  • Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon.

Exclusion

  • Inability to tolerate venous access.
  • Past or present history of active substance abuse (drug or alcohol).
  • * Any active or chronic illness that, in the opinion of the investigators, would make the study unsafe or limit compliance with study procedures.
  • Pregnant females are excluded from this study. All females of child-bearing potential will undergo a serum pregnancy test within 48 hours prior to FBnTP administration.